Fennec Q2 Sales Jump 78% to $17.1M, Swings to Profit
FENC has more than doubled off its 52-week low of $5.65.
Summary
Fennec Pharmaceuticals reported Q2 2026 net product sales of $17.1 million, up 78% year-over-year, and swung to a net profit of $2.0 million. The company also disclosed new 10b5-1 selling plans for its CFO and a director.
Key Events · Earnings and Guidance · FENC
-
PEDMARK Sales Accelerate
Q2 2026 net product sales reached $17.1 million, a 78% increase from $9.7 million in Q2 2025, driven by expanded market penetration and the AYA population.
-
Profitability Inflection
Net income was $2.0 million in Q2 2026 versus a $3.2 million loss a year earlier. Adjusted EBITDA swung to positive $2.8 million from negative $1.2 million.
-
Cash Runway Extended
Cash and cash equivalents totaled $41.2 million as of June 30, 2026. Management states existing cash plus expected revenues fund operations for at least twelve months.
-
New Insider Selling Plans
CFO Robert Andrade adopted a 10b5-1 plan covering up to 75,000 shares, and director Marco Brughera adopted one covering up to 55,545 shares.
Analysis · FENC · Life Sciences
Fennec's second quarter shows accelerating commercial traction for PEDMARK. Net product sales grew 78% year-over-year to $17.1 million, and the company swung from a $3.2 million loss a year ago to a $2.0 million profit. Adjusted EBITDA turned positive at $2.8 million, up from a $1.2 million loss. The company holds $41.2 million in cash and says it has enough to fund operations for at least twelve months. The quarter also reveals two new 10b5-1 selling plans from the CFO and a director, adding modest insider selling pressure over the coming months.
At the time of this filing, FENC was trading at $12.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $418.9M. The 52-week trading range was $5.65 to $13.25. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.